Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Adam Brufsky,Sung-Bae Kim,Z. Zvirbule,Luc Dirix,Alexandru Eniu,Francisco Carabantes,Yann Izarzugaza,Jeroen Mebis,Joohyuk Sohn,Matthew Wongchenko,Saibah Chohan,Reena Amin,V. McNally,David Miles,Sherene Loi

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

2019

Adam Brufsky
Sung-Bae Kim
Z. Zvirbule
Luc Dirix
Alexandru Eniu
Francisco Carabantes
Yann Izarzugaza
Jeroen Mebis
Joohyuk Sohn
Matthew Wongchenko
Saibah Chohan
Reena Amin
V. McNally
David Miles
Sherene Loi

1013Background: COLET showed that the addition of C (MEK1/2 inhibitor) to P resulted in an increased ORR (38%; Brufsky, SABCS 2017); IMpassion130 demonstrated clinical benefit with the combination ...

Keywords:

Cobimetinib
Triple-negative breast cancer
Nab-paclitaxel
Pathology
Paclitaxel
Oncology
Internal medicine
Medicine
Atezolizumab
locally advanced
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations